The first indicates the potential for the drug to overcome a form of acquired resistance to cancer treatment.
The second reveals the “potent activity” of orally administered MRx0518 directly on the human immune system.
Both posters will be showcased at the European Society for Medical Oncology (ESMO) Congress, starting Thursday (September 16). They will be on the company’s website from that date.
MRx0518 is a new class of drug called a live biotherapeutic product (LBP), derived from the microbiome, which is an ecosystem of bacteria found mainly in the human gut.
Delivered in a capsule taken by mouth, it stimulates the body's immune system, directing it to produce cytokines and cells that are known to attack tumours.
It is currently being evaluated in three clinical trials in cancer patients.
“At the core of 4D pharma's platform is the importance of understanding the impact of live biotherapeutics on human biology to rationally select and develop candidates, predict and measure response,” said the company’s chief scientific officer, Dr Alex Stevenson.
“These new biomarker data provide us with critical guidance on the biological and mechanistic impact of MRx0518 therapy in patients with various solid tumours.
"These new findings indicate the potential to predict patients most likely to respond to MRx0518 therapy based on tumour biology."
For more information on the posters click here